By Dan Schell, Editorial Director, Life Science Leader
Becoming the CEO of a pharma company early in the COVID pandemic would be a big challenge for even a seasoned executive in this industry. Just ask David Horn Solomon, Ph.D., who took on the top role at Pharnext in April 2020. But for him, the challenge was two-fold, because the company recently had its Phase 3 trial data rejected by the FDA (for more on this part of the story, read my colleague Ed Miseta’s article on Clinical Leader called, “A Clinical Setback Leads To A Transformation And A New Trial”). We caught up with Solomon in February 2021 to see what he has accomplished so far as he approaches one year on the job.